Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06908694 | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy(GAINPCCONTROL) | active not recruiting | Phase 4 | 20 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07527637 | Risk of Scrotal Hydroceles After Nephrectomy For Kidney Cancer | active not recruiting | — | 40,000 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| 0 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT01318317 | Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 8 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 83 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT01617161 | Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer(PARTIQoL) | active not recruiting | N/A | 454 | Massachusetts General HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01817192 | Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients) | active not recruiting | N/A | 420 | Razor GenomicsINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT01849263 | Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma | active not recruiting | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT01861314 | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02079740 | Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02134925 | Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps | active not recruiting | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 2 | Sep 11, 2026 | clinicaltrials |
| NCT02521285 | Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation | active not recruiting | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Sep 11, 2026 | clinicaltrials |
| NCT02772003 | DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection | active not recruiting | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 2 | Sep 11, 2026 | clinicaltrials |
| NCT02960022 | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | active not recruiting | Phase 2 | 900 | Astellas Pharma Global Development, Inc.INDUSTRY | 38 | Sep 11, 2026 | clinicaltrials |
| NCT03147287 | Palbociclib After CDK and Endocrine Therapy (PACE) | active not recruiting | Phase 2 | 220 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03517137 | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study(COBRA) | active not recruiting | Phase 2 | 150 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 11, 2026 | clinicaltrials |
| NCT03878550 | Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma | active not recruiting | — | 766 | Glycotest, Inc.INDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT03922724 | Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma | active not recruiting | Phase 2 | 91 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04140500 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 170 | Hoffmann-La RocheINDUSTRY | 9 | Sep 11, 2026 | clinicaltrials |
| NCT04162015 | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | active not recruiting | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04191499 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer(INAVO120) | active not recruiting | Phase 2 / Phase 3 | 325 | Hoffmann-La RocheINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT04444921 | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | active not recruiting | Phase 3 | 205 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04485013 | TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 240 | Tizona Therapeutics, IncINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04571138 | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | active not recruiting | Phase 1 / Phase 2 | 35 | Seattle Children's HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04665947 | First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer | active not recruiting | Early Phase 1 | 30 | University of California, DavisOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04739696 | Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.(eCare) | active not recruiting | N/A | 538 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04817826 | TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.(INFINITY) | active not recruiting | Phase 2 | 31 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04820179 | Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer | active not recruiting | Phase 2 | 32 | University of ArizonaOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04875286 | Patient Reported Symptom Control With THC or CBD Use | active not recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04905082 | HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics | active not recruiting | N/A | 465 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04965155 | A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)(ISABEL) | active not recruiting | Phase 2 | 50 | EMN Trial Office S.r.l. Impresa SocialeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05077800 | FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer | active not recruiting | Phase 2 | 70 | Colin D. Weekes, M.D., PhDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05081609 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies(IL Believe) | active not recruiting | Phase 1 / Phase 2 | 320 | Ascendis Pharma Oncology Division A/SINDUSTRY | 10 | Sep 11, 2026 | clinicaltrials |
| NCT05186974 | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)(EVOKE-02) | active not recruiting | Phase 2 | 193 | Gilead SciencesINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 49 | GenmabINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05300282 | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients(FIL_A-BEGEV) | active not recruiting | Phase 1 / Phase 2 | 122 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05470283 | Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | active not recruiting | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05520567 | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 70 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05640193 | A Study of LN-144 in People With Metastatic Melanoma to the Brain | active not recruiting | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05870579 | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | active not recruiting | Phase 1 | 28 | Novartis PharmaceuticalsINDUSTRY | 7 | Sep 11, 2026 | clinicaltrials |
| NCT05983198 | Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT(SatisfACtion) | active not recruiting | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT06055868 | People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity | active not recruiting | — | 133 | University of California, San FranciscoOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06083857 | PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06247995 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.(NeoB-Cap1) | active not recruiting | Phase 1 / Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 11, 2026 | clinicaltrials |
| NCT06251180 | Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 112 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06291220 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(453 Ph1 CLL) | active not recruiting | Phase 1 | 4 | AbbVieINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT06305754 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | active not recruiting | Phase 3 | 550 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
Data updated 17 days agoSource updated Sep 14, 2026source: clinicaltrials